Royal North Shore Hospital

Researchers

• CLChristine Y Lu

Running trials

• Not yet recruiting

  OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma

  NCT07739017· Phase 1· Olivia Newton-John Cancer Research Institute· Source

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Recruiting

  DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

  NCT07707895· Phase 1/2· Boehringer Ingelheim· Source

• Not yet recruiting

  Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease

  NCT07901933· Phase 1· Cajal Therapeutics Inc.· Source

• Not yet recruiting

  Lubricin-inspired Osteoarthritis Treatment: a Unique Solution

  NCT07611708· Pleryon Therapeutics (Hangzhou) Limited· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  NCT07486817· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fibroblast Spheroids) for the Treatment of Refractory Diabetic Foot Ulcers Compared With Standard of Care

  NCT07096934· Phase 1/2· FibroBiologics· Source

• Recruiting

  Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

  NCT07527858· Phase 2· Gilead Sciences· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Recruiting

  A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

  NCT07513376· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

  NCT07491497· Phase 1/2· TRIANA Biomedicines, Inc.· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

  NCT07228117· Medtronic MiniMed, Inc.· Source

• Recruiting

  Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism

  NCT07399977· Memorial Sloan Kettering Cancer Center· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab

  NCT07052877· Royal North Shore Hospital· Source

• Recruiting

  SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

  NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source

• Recruiting

  Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  NCT07223593· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)

  NCT07219771· Phase 3· Doron Therapeutics Inc.· Source

• Recruiting

  Safety, Tolerability and Efficacy of Adjunctive TBO-309 in Reperfusion for Stroke With Tandem Occlusion

  NCT06813651· Phase 2· ThromBio Pty. Ltd.· Source

• Recruiting

  Prostate Adaptive Radiation Therapy

  NCT06547398· Royal North Shore Hospital· Source

• Recruiting

  A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07111520· Phase 1/2· BioNTech SE· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  Post-Operative Prediction of PulmonarY Function

  NCT06494254· University of Sydney· Source

• Recruiting

  Evaluation of Combined Sensitising and Hypomethylating Therapy Outcomes in AML PDX

  NCT06782971· Clinical Hub for Interventional Research (CHOIR)· Source

• Recruiting

  PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

  NCT06961565· Phase 1· Pasithea Therapeutics Corp.· Source

• Recruiting

  A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm

  NCT06991517· World Health Research Inc.· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  NCT06790693· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Amgen· Source

• Recruiting

  A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  NCT06528301· Phase 1· Umoja Biopharma· Source

• Enrolling by invitation

  Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0

  NCT06823115· Indiana University· Source

• Recruiting

  Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy

  NCT06159660· University of Sydney· Source

• Recruiting

  Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  NCT06712355· Phase 3· BioNTech SE· Source

• Recruiting

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· Phase 3· ETOP IBCSG Partners Foundation· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

  NCT06807424· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

  NCT06450886· Phase 2/3· Abcuro, Inc.· Source

• Recruiting

  Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours

  NCT06345079· Phase 2· Australasian Gastro-Intestinal Trials Group· Source

• Recruiting

  Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

  NCT06441747· Phase 2· Australasian Gastro-Intestinal Trials Group· Source

• Active, not recruiting

  A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

  NCT06413498· Phase 3· Kite, A Gilead Company· Source

• Recruiting

  MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy

  NCT05500612· University of Sydney· Source

• Active, not recruiting

  Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

  NCT06449209· Phase 2· BioNTech SE· Source

• Not yet recruiting

  Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke

  NCT06495671· University of Melbourne· Source

• Recruiting

  The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

  NCT06520345· Phase 3· Telix Pharmaceuticals (Innovations) Pty Limited· Source

• Recruiting

  Post-thrombectomy Intra-arterial Tenecteplase for Acute manaGement of Non-retrievable Thrombus and No-reflow in Emergent Stroke

  NCT05892510· Phase 2/3· University of Melbourne· Source

Showing 50 of 119.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer13 recruiting
• Childhood cancers5 recruiting
• Glioblastoma5 recruiting
• Obesity4 recruiting
• Prostate cancer4 recruiting
• Type 2 diabetes4 recruiting
• Chronic kidney disease3 recruiting
• Heart failure3 recruiting
• Neuroendocrine tumours3 recruiting
• Stroke3 recruiting
• Acute myeloid leukaemia2 recruiting
• Aortic stenosis2 recruiting
• Coronary artery disease2 recruiting
• Endometrial cancer2 recruiting
• Head and neck cancer2 recruiting
• High blood pressure2 recruiting
• Liver and biliary tract cancer2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Pancreatic cancer2 recruiting
• Type 1 diabetes2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Colorectal cancer1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Depression1 recruiting
• Diabetic foot ulcer1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Kidney cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Mitochondrial disease1 recruiting
• Neurofibromatosis type 11 recruiting
• Osteoarthritis1 recruiting
• Ovarian cancer1 recruiting
• Peripheral artery disease1 recruiting
• Ventricular tachycardia1 recruiting

Closed trials

• Completed

  A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT06624059· Phase 3· Hoffmann-La Roche· Source

• Withdrawn

  Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM

  NCT02588846· Royal North Shore Hospital· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06326047· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

  NCT06136559· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

  NCT06036836· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

  NCT05721573· Phase 2/3· Abcuro, Inc.· Source

• Completed

  A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05633355· Phase 3· Amgen· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· The George Institute· Source

• Completed

  Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese

  NCT05616013· Phase 2· Eli Lilly and Company· Source

• Completed

  Study of BD Sirolimus Drug Coated Catheter for Treatment of Femoropopliteal Arteries

  NCT05556681· C. R. Bard· Source

• Terminated

  An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

  NCT05267574· Phase 2/3· Reneo Pharma Ltd· Source

• Completed

  A PMCF Study in Patients With Thoracoabdominal Aortic Aneurysms Treated With E-nside TAAA Multibranch Stent Graft System (INNER-B-APAC)

  NCT05954793· JOTEC GmbH· Source

• Completed

  An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)

  NCT05223920· Phase 2· Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)· Source

• Completed

  ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

  NCT05021835· Phase 3· Novo Nordisk A/S· Source

• Completed

  SER150 vs Placebo in Diabetic Kidney Disease

  NCT04881123· Phase 2/3· Serodus AS· Source

• Completed

  A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)

  NCT04659031· Phase 1· Abcuro, Inc.· Source

• Completed

  Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

  NCT03734640· Craig Anderson· Source

• Completed

  A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

  NCT04438304· Phase 2· Clarity Pharmaceuticals Ltd· Source

• Completed

  BRight DCB First-in-Human Study

  NCT04525794· Biotronik CRC Inc.· Source

• Completed

  Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease

  NCT03969953· Phase 3· The George Institute· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Imcyse SA· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· AbbVie· Source

• Completed

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· Phase 3· Hoffmann-La Roche· Source

• Completed

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· Phase 3· Jiangsu HengRui Medicine Co., Ltd.· Source

• Completed

  Safety and Feasibility of Surmodics SUNDANCE™ Drug Coated Balloon

  NCT04107298· SurModics, Inc.· Source

• Completed

  A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

  NCT04285567· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Completed

  Micronised Resveratrol as a Treatment for Friedreich Ataxia

  NCT03933163· Phase 2· Murdoch Childrens Research Institute· Source

• Completed

  Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

  NCT03884101· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

  NCT03635567· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Eisai Inc.· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source

• Completed

  Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry

  NCT03048825· Phase 3· Population Health Research Institute· Source

• Completed

  Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

  NCT02662062· Phase 2· Australian and New Zealand Urogenital and Prostate Cancer Trials Group· Source

• Completed

  Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

  NCT03020303· Phase 3· Hamilton Health Sciences Corporation· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  NCT03036488· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

  NCT02675452· Phase 1· Amgen· Source

• Completed

  Avelumab in First-line NSCLC (JAVELIN Lung 100)

  NCT02576574· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Phase 2· Takeda· Source

• Completed

  A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

  NCT02075840· Phase 3· Hoffmann-La Roche· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

  NCT02003924· Phase 3· Pfizer· Source

• Completed

  ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

  NCT01534819· Medtronic Cardiovascular· Source

• Completed

  Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

  NCT00819208· Canadian Cancer Trials Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Osteoarthritis71 works · 3 trials
• Melanoma69 works · 1 trial
• Obstructive sleep apnoea17 works · 0 trials
• Neuroendocrine tumours15 works · 7 trials
• Thyroid cancer12 works · 2 trials
• High blood pressure4 works · 3 trials